---
title: "Ganaxolone: An Anti-Seizure Medication"
publishedAt: "2024-11-24"
image: "/images/gallery/PresentationMedChem.jpg"
summary: "Every career is a journey, filled with challenges, growth, and those significant moments that mark a shift in our path."
tag: "Medicinal Chemistry"
---

![Ganaxolone Comparison](/images/gallery/PresentationMedChem.jpg)

I had the pleasure of presenting this drug for my 4th-year Medicinal Chemistry class at Trent University. The research process was both challenging and rewarding, giving me a deep appreciation for the effort put into drug discovery and design.

## Background behind the Drug
Ganaxolone was first synthesized and patented in 1976 as part of efforts to explore steroid derivatives with therapeutic potential. Derived from allopregnanolone, an endogenous neurosteroid, its structural modifications enhanced pharmacokinetics, particularly metabolic stability and bioavailability. These innovations make Ganaxolone a noteworthy case study in drug design.

## Structural Overview and Pharmacokinetics
Ganaxolone (3α-hydroxy-3β-methyl-5α-pregnan-20-one) is a synthetic analog of allopregnanolone. The addition of a β-methyl group at the C3 position prevents metabolic oxidation, enhancing stability and oral bioavailability.

![Ganaxolone Comparison](/images/projects/project-01/SidebySideGanaxolone.png) **Figure 1:** Ganaxolone molecular structure (right) and its FDA-approved formulation, ZTALMY (left).

ZTALMY, the prescription form of Ganaxolone, was administered as an oral liquid suspension (50 mg/mL). The drug was absorbed in the small intestine and entered systemic circulation. Its high lipophilicity facilitated passive diffusion across the lipid bilayer, enabling rapid distribution to tissues, including the central nervous system (CNS). Upon reaching the brain, Ganaxolone crossed the blood-brain barrier effectively, leveraging its structural properties and high LogP value of 4.27 to access its target receptors. In circulation, it underwent extensive hepatic metabolism primarily mediated by cytochrome P450 enzymes, with hydroxylation at the C16 position being the major pathway.

![Ganaxolone Comparison](/images/projects/project-01/CYP450.png) **Figure 2:** (a) Hydroxylation of Ganaxolone at the C16 position; (b) CYP450 enzyme involved in metabolism.

## Key Functional Groups and GABA-A Receptor Interaction
Ganaxolone’s therapeutic effects stem from its interaction with the GABA-A receptor, where key functional groups enhance binding:

- **C3 hydroxyl group:** Facilitates hydrogen bonding.
- **C20 ketone group:** Acts as a hydrogen bond acceptor.
- **C3 β-methyl group:** Enhances lipophilicity and receptor binding via van der Waals forces.

![Ganaxolone Comparison](/images/projects/project-01/Comparison3.png) **Figure 3:** (a) 2D structure with functional groups labeled; (b) 3D topological map of Ganaxolone.

At the receptor site, these interactions stabilize conformations that increase the receptor’s affinity for GABA, promoting chloride influx into neurons and reducing CNS excitability.

![Ganaxolone Comparison](/images/projects/project-01/GABA.png) **Figure 4:** Binding interactions at GABA-A receptor sites.

## Clinical Development and Applications
Ganaxolone’s development spanned decades, culminating in FDA approval for treating seizures associated with Cyclin-Dependent Kinase-Like 5 Deficiency Disorder (CDD) in 2022. Its efficacy was confirmed in the Phase III Marigold trial, though the Phase III RAISE trial for refractory status epilepticus faced challenges. It currently has an orphan drug status and is the only medication used to treat seizures associated with CDD in the market.

![Ganaxolone Comparison](/images/projects/project-01/CDD.png) **Figure 5:** (a) CDKL5 Deficiency Disorder is an X-linked brain disorder characterized by mutations in the CDKL5 gene, leading to (b) dysfunctional CDKL5 protein. This protein plays a crucial role in neuronal development through key phosphorylation events, and its disruption results in improper dendritic growth. (c) Consequently, an imbalance of excitatory and inhibitory signals emerges in the nervous system, contributing to severe, refractory seizures in affected individuals. However, Ganaxolone restores normal brain function via balancing excitatory and inhibited neuronal signals

## Example Synthesis of Ganaxolone
Using the synthesis of Ganaxolone from Lenna et al. (2022), it involved four key steps:

1. **Ketalization:** Protects the C20 ketone group, yielding an intermediate.
2. **Nitroxide-Catalyzed Oxidation:** Converts the C3 hydroxyl to a ketone.
3. **Grignard Reaction:** Introduces the β-methyl group at the C3 position.
4. **Ketal Deprotection:** Regenerates the C20 ketone group using iodine.

![Ganaxolone Comparison](/images/projects/project-01/synthesis1.png) **Figure 6:** Full Ganaxolone synthesis.

## Challenges and Future Directions
Despite its efficacy, Ganaxolone’s high cost as an orphan drug raises accessibility concerns due to high market cost. Research into alternative synthetic routes or cost-reducing measures could improve affordability. Ganaxolone exemplifies the power of structural modifications in drug design, balancing therapeutic efficacy with metabolic stability. As a positive allosteric modulator of GABA-A receptors, it provides hope for rare seizure disorders while highlighting challenges in drug affordability and accessibility.

## References:

1.	Cook, M. C.; Lawrence, R.; Phillipps, G. H.; Hunter, A. C.; Newall, C. E.; Stephenson, L.; Weir, N. G. Anaesthetic Steroids of the Androstance and Pregnane Series. U.S. Patent 3,953,429, April 27, 1976. 

2.	Reddy, D. S. Pharmacology of Endogenous Neuroactive Steroids. Crit. Rev. Neurobiol. 2003, 15 (3–4), 197–234. 

3.	Lenna, R.; Fasana, A.; Delfrate, C.; Ortiz Blacio, J. D. Process for preparing (3α,5α)-3-hydroxy-3-methyl-pregnan-20-one (Ganaxolone). WO 2022053937 A1, 2022 

4.	Carter, R. B.; Wood, P. L.; Wieland, S.; Hawkinson, J. E.; Belelli, D.; Lambert, J. J.; White, H. S.; Wolf, H. H.; Mirsadeghi, S.; Tahir, S. H.; Bolger, M. B.; Lan, N. C.; Gee, K. W. Characterization of the Anticonvulsant Properties of Ganaxolone (CCD 1042; 3α-Hydroxy-3β-Methyl-5α-Pregnan-20-One), a Selective, High-Affinity, Steroid Modulator of the γ-Aminobutyric AcidA Receptor. J. Pharmacol. Exp. Ther. 1997, 280 (3), 1284–1295. 

5.	DrugBank. Ganaxolone. https://go.drugbank.com/drugs/DB05087 (accessed Dec 3, 2024). 

6.	U.S. Food and Drug Administration. FDA Approves Drug for Treatment of Seizures Associated with Rare Disease in Patients Two Years of Age and Older. U.S. Food and Drug Administration. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treatment-seizures-associated-rare-disease-patients-two-years-age-and-older (accessed Dec 3, 2024). 

7.	Health Canada. New Medicines Approved in 2022 - Meds Entry Watch. Government of Canada. https://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/meds-entry-watch-8th-edition/new-medicines-approved-2022.html (accessed Dec 3, 2024). 

8.	Marinus Pharmaceuticals. Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (Ganaxolone) Phase 3 Marigold Trial Results. Marinus Pharmaceuticals. https://ir.marinuspharma.com/news/news-details/2022/Marinus-Pharmaceuticals-Announces-Publication-in-The-Lancet-Neurology-of-ZTALMY-ganaxolone-Phase-3-Marigold-Trial-Results/default.aspx (accessed Nov 24, 2024). 

9.	Fitch, W. L.; Smith, S.; Saporito, M.; Busse, G.; Zhang, M.; Ren, J.; Fitzsimmons, M. E.; Yi, P.; English, S.; Carter, A.; Baillie, T. A. Complex Metabolism of the Novel Neurosteroid Ganaxolone in Humans: A Unique Challenge for Metabolites in Safety Testing Assessment. Drug Metab. Dispos. 2023, 51 (6), 753–763. 

10.	Gay, S. C.; Shah, M. B.; Talakad, J. C.; Maekawa, K.; Roberts, A. G.; Wilderman, P. R.; Sun, L.; Yang, J. Y.; Huelga, S. C.; Hong, W.-X.; Zhang, Q.; Stout, C. D.; Halpert, J. R. Crystal Structure of a Cytochrome P450 2B6 Genetic Variant in Complex with the Inhibitor 4-(4-Chlorophenyl)Imidazole at 2.0 Å Resolution. Mol. Pharmacol. 2010, 77 (4), 529–538. 

11.	U.S. Food and Drug Administration. ZTALMY® (Ganaxolone) Oral Suspension. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215904s000lbl.pdf (accessed 2024-11-23) 

12.	Hill, S. CHEM 4300 – Bioinorganic Chemistry; Trent University: Peterborough, ON, 2024.

13.	Rafferty, S. CHEM 3320 – Metabolism; Trent University: Peterborough, ON, 2023.
14.	Moss, G. P. Nomenclature of Steroids (Recommendations 1989). Pure Appl. Chem. 1989, 61 (10), 1783–1822. 

15.	Wu, D.; Chen, Q.; Chen, X.; Han, F.; Chen, Z.; Wang, Y. The Blood–Brain Barrier: Structure, Regulation, and Drug Delivery. Signal Transduct. Target. Ther. 2023, 8 (1), 1–27. 

16.	Marinus Pharmaceuticals. Figure 3. Schematic of GABAergic Inhibition at Both Synaptic and Extrasynaptic Receptor Sites and Effect (EC 50 ) of NAS at Both Receptor Types Ganaxolone: Mechanism of Action and Pharmacology Conclusions • GNX Is a Positive Allosteric Modulator of GABA A; 2020. https://marinuspharma.com/wp-content/uploads/2020/12/1_AES2020_GNX-Mechanism-of-Action.pdf (accessed 2024-11-25). 

17.	Reddy, D. S. Neurosteroids as Novel Anticonvulsants for Refractory Status Epilepticus and Medical Countermeasures for Nerve Agents: A 15-Year Journey to Bring Ganaxolone from Bench to Clinic. J. Pharmacol. Exp. Ther. 2024, 388(2):273-300. 

18.	Hosie, A. M.; Wilkins, M. E.; Smart, T. G. Neurosteroid Binding Sites on GABAA Receptors. Pharmacology & Therapeutics 2007, 116 (1), 7–19. 

19.	Yasmen, N.; Sluter, M. N.; Yu, Y.; Jiang, J. Ganaxolone for Management of Seizures Associated with CDKL5 Deficiency Disorder. Trends Pharmacol. Sci. 2023, 44 (2), 128–129. 

20.	van Bergen, N. J.; Massey, S.; Quigley, A.; Rollo, B.; Harris, A. R.; Kapsa, R. M. I.; Christodoulou, J. CDKL5 Deficiency Disorder: Molecular Insights and Mechanisms of Pathogenicity to Fast-Track Therapeutic Development. Biochem. Soc. Trans. 2022, 50 (4), 1207–1224. 

21.	Marinus Pharmaceuticals. Ganaxolone Phase 1 Data Supports Progressing to Phase 2 in Patients with Status Epilepticus. Marinus Pharmaceuticals. https://ir.marinuspharma.com/news/news-details/2016/Ganaxolone-Phase-1-Data-Supports-Progressing-to-Phase-2-in-Patients-with-Status-Epilepticus/default.aspx (accessed Nov 24, 2024). 

22.	Marinus Pharmaceuticals. Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-Term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients. https://ir.marinuspharma.com/news/news-details/2018/Marinus-Pharmaceuticals-Phase-2-Clinical-Trial-Data-Show-Long-term-Effectiveness-of-Ganaxolone-in-Reducing-Seizure-Frequency-in-CDKL5-Deficiency-Disorder-Patients/default.aspx (accessed Nov 24, 2024). 

23.	Marinus Pharmaceuticals. Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus. https://ir.marinuspharma.com/news/news-details/2024/Marinus-Pharmaceuticals-Announces-Topline-Results-from-Phase-3-RAISE-Trial-of-IV-Ganaxolone-in-Refractory-Status-Epilepticus/default.aspx (accessed Dec 3, 2024). 

24.	Reddy, D. S.; Woodward, R. M. Ganaxolone: A Prospective Overview. Drugs Future 2004, 29 (3), 193–202. 
25.	Marinus Pharmaceuticals. FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder. https://ir.marinuspharma.com/news/news-details/2017/FDA-Grants-Orphan-Drug-Designation-for-Ganaxolone-in-CDKL5-Disorder/default.aspx (accessed Dec 3, 2024). 

26.	Bobbitt, J. M.; Brückner, C.; Merbouh, N. Oxoammonium-Salt Oxidations of Alcohols: The Mechanism of the TEMPO Reaction. Org. Synth. 2009, 86, 162–175. 

27.	Okada, T. Studies on Oxidation Reactions Using Sodium Hypochlorite Pentahydrate. Org. Synth. 1998, Coll. Vol. 11, 106–132.

28.	Reddy, S. R.; Chadha, A. A Simple and Efficient Method for Mild and Selective Oxidation of Propargylic Alcohols Using TEMPO and Calcium Hypochlorite. RSC Advances 2013, 3 (35), 14929. 

29.	Dess, D. B.; Martin, J. C. Readily Accessible 12-I-51 Oxidant for the Conversion of Primary and Secondary Alcohols to Aldehydes and Ketones. J. Org. Chem. 1983, 48, 4155–4156. 

30.	Omura, K.; Swern, D. Oxidation of Alcohols by “Activated” Dimethyl Sulfoxide. A Preparative, Steric and Mechanistic Study. Tetrahedron 1978, 34 (11), 1651–1660. 

31.	Iwabuchi, Y. Discovery and Exploitation of AZADO: The Highly Active Catalyst for Alcohol Oxidation. Chemical and Pharmaceutical Bulletin 2013, 61 (12), 1197–1213. 

32.	Fujifilm Wako Chemicals. nor-AZADO; 2024. 

33.	n-Butyllithium solution; CAS RN: 109-72-8, CAS RN: 110-82-7. Sigma-Aldrich Product Number: 302120; Sigma-Aldrich: October 2, 2024. 

34.	Sun, J.; Dong, Y.; Cao, L.; Wang, X.; Wang, S.; Hu, Y. Highly Efficient Chemoselective Deprotection of O,O-Acetals and O,O-Ketals Catalyzed by Molecular Iodine in Acetone. The Journal of Organic Chemistry 2004, 69 (25), 8932–8934. 
35.	Dunleavy, K. Marinus Pharmaceuticals Scores an FDA Nod for Ztalmy, the First Drug for Rare Genetic Epileptic Condition. Fierce Pharma, March 18, 2022. https://www.fiercepharma.com/pharma/marinus-scores-approval-ztalmy-first-drug-rare-genetic-epileptic-condition-cdd (accessed Dec 2, 2024). 

36.	Snead, O. C. Ganaxolone, a Selective, High-Affinity Steroid Modulator of the ?-Aminobutyric Acid-A Receptor, Exacerbates Seizures in Animal Models of Absence. Annals of Neurology 1998, 44 (4), 688–691. 

37.	Supporting CDKL5. The Story of CDKL5. https://www.supporting-cdkl5.co.uk/story-of-cdkl5.php (accessed Dec 13, 2024).

38.	Olson, H. E.; Demarest, S. T.; Pestana-Knight, E. M.; Swanson, L. C.; Iqbal, S.; Lal, D.; Leonard, H.; Cross, J. H.; Devinsky, O.; Benke, T. A. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review. Epilepsy Behav. 2019, 93, 228–236.
